The FDA rejected ivonescimab, a PD-1 x VEGF treatment developed by Summit Therapeutics and Akeso, citing the lack of a survival benefit despite evidence of slowing disease progression. The agency concluded that the absence of improved overall survival undermined the drug’s benefit-risk profile for approval. The rejection is a regulatory setback for Summit’s path outside China and underscores the threshold agencies apply to confirm meaningful survival outcomes. It also comes after leadership changes reported by the company, raising near-term uncertainty about trial follow-through and development strategy. Biopharma stakeholders will watch for whether Summit revises the program, seeks alternate endpoints, or reallocates resources to other assets after the negative FDA action.